These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37777450)

  • 21. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
    Laufer RS; Driscoll AJ; Baral R; Buchwald AG; Campbell JD; Coulibaly F; Diallo F; Doumbia M; Galvani AP; Haidara FC; Kotloff KL; Keita AM; Neuzil KM; Orenstein EW; Orenstein LAV; Pecenka C; Sow S; Tapia MD; Ortiz JR; Fitzpatrick MC
    Vaccine; 2021 Aug; 39(35):5037-5045. PubMed ID: 34325934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
    MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study.
    Li X; Hodgson D; Flaig J; Kieffer A; Herring WL; Beyhaghi H; Willem L; Jit M; Bilcke J; Beutels P;
    Value Health; 2023 Apr; 26(4):508-518. PubMed ID: 36442831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries.
    Carbonell-Estrany X; Rodgers-Gray BS; Paes B
    Expert Rev Anti Infect Ther; 2021 Apr; 19(4):419-441. PubMed ID: 32972198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study.
    Do LAH; Vodicka E; Nguyen A; Le TNK; Nguyen TTH; Thai QT; Pham VQ; Pham TU; Nguyen TN; Mulholland K; Cao MT; Le NTN; Tran AT; Pecenka C
    BMC Infect Dis; 2023 Feb; 23(1):73. PubMed ID: 36747128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Herring WL; Zhang Y; Shinde V; Stoddard J; Talbird SE; Rosen B
    Vaccine; 2022 Jan; 40(3):483-493. PubMed ID: 34933763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review.
    Prescott WA; Doloresco F; Brown J; Paladino JA
    Pharmacoeconomics; 2010; 28(4):279-93. PubMed ID: 20131925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: a literature review.
    Lang JC
    J Math Biol; 2022 Feb; 84(4):26. PubMed ID: 35218424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory syncytial virus immune globulin: decisions and costs.
    Barton LL; Grant KL; Lemen RJ
    Pediatr Pulmonol; 2001 Jul; 32(1):20-8. PubMed ID: 11416872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study.
    Fortunato F; Campanozzi A; Maffei G; Arena F; Carri VD; Rollo T; Lopalco PL; Martinelli D
    Ital J Pediatr; 2024 Mar; 50(1):45. PubMed ID: 38454523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
    Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
    Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RSV vaccine use--the missing data.
    Drysdale SB; Sande CJ; Green CA; Pollard AJ
    Expert Rev Vaccines; 2016; 15(2):149-52. PubMed ID: 26636902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.